Akari Narrows Losses, Shifts Focus to ADC Platform Post-Peak Bio Merger

TL;DR

**AKTX is burning cash and needs more funding, but their R&D pivot could be a game-changer if they can execute.**

AI Summary

Akari Therapeutics Plc (AKTX) reported a net loss of $5.6 million for the six months ended June 30, 2025, a significant improvement from the $13.124 million net loss in the same period of 2024. Research and development expenses decreased substantially to $1.480 million for the six months ended June 30, 2025, down from $5.593 million in 2024, reflecting a strategic shift post-acquisition. General and administrative expenses slightly increased to $5.164 million from $4.907 million year-over-year. The company recorded a gain on settlement of current liabilities of $1.244 million for the six months ended June 30, 2025, contributing to the reduced net loss. Cash on hand as of June 30, 2025, was $2.711 million, a slight increase from $2.599 million at December 31, 2024, but insufficient to fund operations for the next year. Total liabilities decreased to $25.306 million from $28.333 million, primarily due to reductions in accounts payable and notes payable. The company's strategic outlook is focused on its ADC platform utilizing the PH1 spliceosome modulator for cancer treatment, following the acquisition of Peak Bio in November 2024.

Why It Matters

Akari's significant reduction in net loss and R&D expenses, coupled with a strategic pivot to its ADC platform, signals a critical juncture for investors. While the company improved its financial burn rate, the $2.7 million cash balance raises substantial going concern doubts, indicating a high likelihood of further dilutive financing. This shift could position Akari to compete in the lucrative oncology market, but its ability to secure funding and advance its PH1 payload will determine its long-term viability against larger, well-capitalized biotech firms. Employees face uncertainty given the ongoing need for capital, and customers (future patients) depend on successful clinical development.

Risk Assessment

Risk Level: high — The company's cash balance of $2.7 million as of June 30, 2025, is insufficient to fund operations for the one-year period after the financial statements were issued, raising substantial doubt about its ability to continue as a going concern. This is explicitly stated in Note 1, 'Liquidity and Financial Condition'. Additionally, the company has an accumulated deficit of $252.9 million, indicating a history of significant losses.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Monitor closely for any announcements regarding new financing rounds or strategic collaborations, as these will be critical for the company's survival and ability to advance its ADC platform. Without significant new capital, the stock faces substantial downside risk.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

$25.306M

net Income

-$5.6M

eps

N/A

gross Margin

N/A

cash Position

$2.711M

revenue Growth

N/A

Key Numbers

• $2.7M — Cash balance (Insufficient to fund operations for one year, up from $2.599M at Dec 31, 2024)
• $5.6M — Net loss (six months) (Reduced from $13.124M in prior year period)
• $1.48M — Research and development expenses (six months) (Decreased from $5.593M in prior year period)
• $252.9M — Accumulated deficit (As of June 30, 2025, indicating substantial historical losses)
• $1.244M — Gain on settlement of current liabilities (six months) (Contributed to reduced net loss)
• 65,229,461,523 — Ordinary Shares outstanding (As of August 13, 2025, significantly increased from 53,186,919,523 at Dec 31, 2024)
• $25.306M — Total liabilities (Decreased from $28.333M at Dec 31, 2024)

Key Players & Entities

• Akari Therapeutics Plc (company) — registrant
• Peak Bio, Inc. (company) — acquired company
• PH1 (other) — novel anti-cancer payload
• Securities and Exchange Commission (regulator) — filing oversight
• Nasdaq Capital Market (other) — stock exchange
• Pegasus Merger Sub, Inc. (company) — wholly-owned subsidiary of Akari
• FASB Accounting Standards Codification 205-40 (other) — going concern accounting standard

FAQ

Risk Factors

• Product Development Uncertainty [high — operational]: Akari Therapeutics faces significant risks inherent in pre-clinical and clinical stage companies, including the uncertainty of product development. The success of its ADC platform utilizing the PH1 spliceosome modulator for cancer treatment is not guaranteed, and failure could delay or terminate research activities.
• Dependence on External Capital [high — financial]: The company's ability to execute its business plan is heavily reliant on raising capital. With only $2.711 million in cash as of June 30, 2025, which is insufficient to fund operations for the next year, Akari faces a substantial risk if it cannot secure additional funding.
• Reliance on Key Personnel and Collaborators [medium — operational]: Akari's operations depend on key individuals and third-party collaborators for research and development. Any disruption or loss of these resources could significantly impact the company's progress and ability to bring its ADC candidates to market.
• Need for Marketing Authorization [high — regulatory]: The company requires marketing authorization for its products, which involves complex and lengthy regulatory processes. Failure to obtain these approvals would prevent commercialization of its ADC candidates.
• Competition from Larger Companies [medium — market]: Akari operates in a competitive landscape and faces competition from larger, better-capitalized companies. These competitors may have more resources for research, development, and marketing, posing a significant challenge to Akari's market entry.
• Intellectual Property Protection [medium — operational]: Protecting its intellectual property is crucial for Akari's ADC platform. Risks associated with intellectual property protection could undermine the company's competitive advantage and future revenue generation.

Industry Context

Akari Therapeutics operates in the highly competitive and rapidly evolving biotechnology sector, specifically focusing on the development of Antibody-Drug Conjugates (ADCs) for cancer treatment. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Key trends include the advancement of targeted therapies, the increasing sophistication of payload delivery systems, and the potential for ADCs to overcome limitations of traditional chemotherapy and immunotherapy.

Regulatory Implications

As a clinical-stage biotechnology company, Akari faces significant regulatory scrutiny. The development and approval process for its ADC candidates, particularly those utilizing novel payloads like PH1, will require extensive pre-clinical and clinical trials to demonstrate safety and efficacy to regulatory bodies such as the FDA and EMA. Failure to meet these rigorous standards could result in significant delays or outright rejection of product candidates.

What Investors Should Do

1. Monitor cash burn and future financing activities.
2. Track progress of the PH1 ADC platform and clinical trial updates.
3. Assess competitive landscape and intellectual property.

Key Dates

• 2024-11-14: Completion of Peak Bio Acquisition — This strategic business combination marked a significant shift, with Akari focusing substantially all its efforts on its ADC platform utilizing the PH1 spliceosome modulator.
• 2025-06-30: End of Six-Month Period — Reporting period for the condensed consolidated financial statements, showing a reduced net loss and decreased R&D expenses.

Glossary

ADCs

Antibody-drug conjugates, which are biopharmaceutical drugs composed of an antibody-targeting moiety and a cytotoxic drug payload. (Akari Therapeutics is developing next-generation ADCs through its proprietary technology platform.)

Spliceosome Modulator

A type of molecule that interferes with the function of the spliceosome, a cellular machine responsible for RNA splicing. (Akari's ADC platform utilizes PH1, a novel anti-cancer payload that is a spliceosome modulator.)

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Akari has an accumulated deficit of $252.9 million as of June 30, 2025, indicating substantial historical losses.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, without the threat of liquidation. (The financial statements are prepared assuming Akari will continue as a going concern, despite its current cash position.)

Year-Over-Year Comparison

Compared to the prior year period, Akari Therapeutics has significantly reduced its net loss from $13.124 million to $5.6 million for the six months ended June 30, 2025. This improvement is largely driven by a substantial decrease in research and development expenses, from $5.593 million to $1.480 million, reflecting a strategic shift post-acquisition. While general and administrative expenses saw a slight increase, a gain on settlement of current liabilities also contributed to the reduced net loss. The company's cash position has slightly improved, but remains a concern for near-term operational sustainability.

Key Financial Figures

• $0.0001 — enting 2,000 Ordinary Shares, par value $0.0001 per share AKTX The Nasdaq Capital M

Filing Documents

• form10-q.htm (10-Q) — 1309KB
• ex10-2.htm (EX-10.2) — 70KB
• ex10-3.htm (EX-10.3) — 49KB
• ex10-4.htm (EX-10.4) — 22KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 18KB
• ex32-1.htm (EX-32.1) — 8KB
• ex32-2.htm (EX-32.2) — 8KB
• 0001641172-25-023569.txt ( ) — 7401KB
• aktx-20250630.xsd (EX-101.SCH) — 61KB
• aktx-20250630_cal.xml (EX-101.CAL) — 61KB
• aktx-20250630_def.xml (EX-101.DEF) — 301KB
• aktx-20250630_lab.xml (EX-101.LAB) — 516KB
• aktx-20250630_pre.xml (EX-101.PRE) — 410KB
• form10-q_htm.xml (XML) — 1149KB

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Condensed Consolidated Balance Sheets 1 Condensed Consolidated Statements of Operations and Comprehensive Loss 2 Condensed Consolidated Statements of Shareholders' Equity (Deficit) 3 Condensed Consolidated Statements of Cash Flows 5 Notes to Unaudited Condensed Consolidated Financial Statements 6 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 36 Item 4.

Controls and Procedures

Controls and Procedures 37 PART II OTHER INFORMATION 38 Item 1.

Legal Proceedings

Legal Proceedings 38 Item 1A.

Risk Factors

Risk Factors 3 8 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 38 Item 3. Defaults Upon Senior Securities 38 Item 4. Mine Safety Disclosures 38 Item 5. Other Information 38 Item 6. Exhibits 39

SIGNATURES

SIGNATURES 40 i GENERAL INFORMATION Unless otherwise stated or the context requires otherwise, references in this Quarterly Report on Form 10-Q ( "Form 10-Q") to "Akari," the "company," the "Company," "we," "us," "our" or similar designations refer to Akari Therapeutics, Plc and its subsidiaries, taken together. All trademarks, service marks, trade names and registered marks used in this report are trademarks, trade names or registered marks of their respective owners. made in this Form 10-Q concerning the contents of any agreement, contract or other document are summaries of such agreements, contracts or documents and are not complete description of all of their terms. If we filed any of these agreements, contracts or documents as exhibits to this Form 10-Q or to any previous filing with the Securities and Exchange Commission ("SEC"), you may read the document itself for a complete understanding of its terms. ii NOTE REGARDING FORWARD-LOOKING STATEMENTS This Form 10-Q and the documents we incorporate by reference contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements, other than statements of historical fact, included or incorporated in this report regarding, among other things, our cash resources and projected cash runway, financial position, our strategy, strategic alternatives, future operations, clinical trials (including, without limitation, the anticipated timing enrollment, and results thereof), collaborations, intellectual property, future revenues, projected costs, fundraising and/or financing plans, prospects, developments relating to our competitors and our industry, the timing or likelihood of regulatory actions, filings and approvals for our current and future drug candidates, and the plans and objectives of management are forward-looking stateme

Business

Business Overview Akari Therapeutics, Plc, (the "Company" or "Akari") is incorporated in the United Kingdom. The Company is developing next-generation antibody-drug conjugates, or ADCs, through its proprietary technology platform of novel payloads, enabling Akari to generate multiple ADC candidates to target a range of cancers. On March 4, 2024, the Company entered into an Agreement and Plan of Merger (the "Merger Agreement") with Peak Bio, Inc. ("Peak Bio") and Pegasus Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Akari ("Merger Sub"). On November 14, 2024, the Company completed the previously announced strategic business combination contemplated by the Merger Agreement ("Closing"), pursuant to which, Merger Sub merged with and into Peak Bio, with Peak Bio surviving the acquisition as a wholly owned subsidiary of Akari. Since the Company's acquisition of Peak Bio in November 2024, Akari has focused substantially all of its efforts on its ADC platform utilizing a novel anti-cancer payload called PH1, a spliceosome modulator. Through its payload platform, the Company aims to establish a pipeline of ADC candidates that target and directly kill cancer cells, while also activating the immune system to provide for potentially more durable and sustained efficacy and responses, thereby overcoming limitations inherent in existing ADC therapies. The Company's activities since inception have consisted of performing research and development activities and raising capital. The Company is subject to a number of risks similar to those of pre-clinical and clinical stage companies, including dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with clinical trials of products, dependence on third-party collaborators for research and development operations, need for marketing authorization of products, risks associated with protection of intellectual

View Full Filing

View this 10-Q filing on SEC EDGAR